Nonetheless, our findings with WEE1 inhibitors and Sotorasib suggest WEE1 inhibitors may enhance the efficacy of KRAS-targeted therapies, improving clinical outcomes in KRAS-mutant lung cancer. The gene discussed is WEE1; the disease is lung carcinoma.